Last Update 15 Apr 26

ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand

Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement.

Analyst Commentary

Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility. Here is how the Street commentary broadly splits out.

Bullish Takeaways

Bullish analysts see Roche pricing its Axelios consumables at $150 per genome duplex as supportive for Illumina, since it comes in above some expectations and leaves Illumina's $200 list price, with typical discounts to around $150 to $180, looking more defendable.
Several firms have lifted their Illumina price targets in recent weeks. This signals confidence that the current fair value estimate around $136.11 per share still aligns with their views on execution and long term adoption of sequencing.
Target raises from multiple houses suggest that, even with competitive announcements, bullish analysts view Illumina's product and pricing position as strong enough to support their growth assumptions.
The clustering of upward target revisions around similar dates indicates some alignment that recent news flow, including competitor pricing, reduces near term downside risk to the existing valuation framework.

Bearish Takeaways

Bearish analysts have trimmed price targets, indicating concern that execution, profitability, or growth visibility may not fully support the more optimistic scenarios embedded in higher targets.
Target cuts point to caution around how quickly Illumina can translate its installed base and pricing into earnings power that justifies a higher valuation multiple.
The coexistence of both raised and lowered targets suggests that not all analysts are convinced that competitive pricing news meaningfully improves the risk reward, keeping some pressure on expectations.
Investors should recognize that these lower targets imply a view that current or prior market expectations might be ahead of what bearish analysts see as achievable on growth and margin execution.

What's in the News

Illumina and the Center for Data-Driven Discovery in Biomedicine are partnering on one of the largest unified pediatric genomic datasets, targeting analysis of 100,000 whole genomes to support cancer and rare disease research via cloud-based platforms and the Gabriella Miller Kids First Data Resource Center (Key Developments).
Illumina and Labcorp expanded their collaboration to broaden access to cancer biomarker testing, including co-commercialization of Labcorp's PGDx elio plasma focus Dx with Illumina's TruSight Oncology Comprehensive and joint work on new in vitro diagnostic and research tests across precision oncology (Key Developments).
Illumina launched TruPath Genome, a whole genome workflow priced at US$395 per genome that targets high accuracy in difficult genomic regions, higher throughput compared with some long read methods, and support for complex rare disease research, with early access use across multiple academic and clinical centers (Key Developments).
Illumina outlined an 18 month roadmap for NovaSeq X that targets Q70 quality scores, higher output up to 35b reads, faster runtimes, and new batching options, with the goal of supporting applications such as molecular residual disease testing and large scale genomics studies (Key Developments).
Illumina issued fiscal 2026 guidance for total revenue of US$4.5b to US$4.6b, with the company stating this reflects 4% to 6% reported growth and a 1.5% to 2.0% contribution from the SomaLogic acquisition (Key Developments).

Valuation Changes

Fair Value: The $136.11 per share fair value estimate is unchanged, indicating no adjustment to the central valuation anchor.
Discount Rate: The discount rate has risen slightly from 8.07% to 8.10%, implying a modestly higher required return in the model.
Revenue Growth: The long term revenue growth assumption has been trimmed from 5.44% to 5.14%, reflecting a slightly more conservative outlook for top line expansion.
Net Profit Margin: The modeled net profit margin has edged up from 20.11% to 20.28%, pointing to a small improvement in expected profitability.
Future P/E: The future P/E multiple assumption is broadly stable, remaining at 23.0x, so valuation still leans on a similar earnings multiple.

16 views

Key Takeaways

Expansion in clinical genomics and next-generation sequencing adoption is driving strong, recurring revenue growth and future earnings visibility.
Ongoing innovation, multiomics expansion, and operational efficiency are enhancing gross margins and creating new growth opportunities.
Persistent research budget constraints, regulatory risks in China, rising competition, commoditization, and clinical dependency threaten Illumina's revenue growth, margins, and market position.

Catalysts

About Illumina

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.What are the underlying business or industry changes driving this perspective?

Strong and resilient growth in clinical applications-especially oncology, genetic disease testing, and reproductive health-continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.
Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.
Ongoing innovation-evidenced by successful launches like MiSeq i100 Plus and increasing uptake of NovaSeq X-lowers barriers for new customer segments, enhances platform performance, and supports higher gross margins as transitions accelerate, particularly in the clinical segment.
Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, contributing to future revenue and operating margin expansion.
Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling-along with tax headwinds turning into tailwinds-sets the stage for continued net margin and earnings growth over the next several years.

Illumina Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Illumina's revenue will grow by 5.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 19.6% today to 20.3% in 3 years time.
Analysts expect earnings to reach $1.0 billion (and earnings per share of $6.59) by about April 2029, up from $850.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.2 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.1x on those 2029 earnings, down from 23.4x today. This future PE is lower than the current PE for the US Life Sciences industry at 39.0x.
Analysts expect the number of shares outstanding to decline by 3.41% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.1%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heightened U.S. research funding uncertainty and ongoing NIH budget constraints are leading to persistent softness in the research end-market, significantly limiting instrument purchases and creating a negative long-term headwind for revenue growth and earnings diversification.
Increased export restrictions and regulatory uncertainties in China are causing a sustained decline in Chinese instrument and consumables revenue; management notes the situation is currently unsustainable, indicating elevated risk to international revenue streams and future top-line growth.
Intensifying competition, particularly from upcoming platforms like Roche's with faster turnaround times, poses the risk of price pressure, potential market share loss, and margin compression, especially as the market for high
and mid-throughput sequencing matures.
There is ongoing commoditization of next-generation sequencing (NGS) technology as well as a shift towards decentralized, benchtop sequencers like the MiSeq i100, which could lower barriers for competitors, shift purchasing patterns, and erode gross margins and operating leverage over time.
The company's dependence on continued strong growth in clinical applications carries risk; if clinical adoption or reimbursement slows, demand for sequencing platforms and consumables could weaken, leading to lower revenue growth and potential negative impact on earnings and margins, especially as clinical now makes up over 60% of consumables revenue.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $136.11 for Illumina based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $170.0, and the most bearish reporting a price target of just $80.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $5.0 billion, earnings will come to $1.0 billion, and it would be trading on a PE ratio of 23.1x, assuming you use a discount rate of 8.1%.
Given the current share price of $130.32, the analyst price target of $136.11 is 4.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Illumina?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties